181 related articles for article (PubMed ID: 4040978)
1. Treatment of hypertrophic cardiomyopathy: relation to pathological mechanisms.
Kaltenbach M; Hopf R
J Mol Cell Cardiol; 1985 Jul; 17 Suppl 2():59-68. PubMed ID: 4040978
[TBL] [Abstract][Full Text] [Related]
2. [Conservative medical treatment of hypertrophic myocardiopathies].
Kaltenbach M; Hopf R
Z Kardiol; 1982 Dec; 71(12):795-805. PubMed ID: 6891871
[TBL] [Abstract][Full Text] [Related]
3. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy.
Rosing DR; Idänpään-Heikkilä U; Maron BJ; Bonow RO; Epstein SE
Am J Cardiol; 1985 Jan; 55(3):185B-195B. PubMed ID: 3881913
[TBL] [Abstract][Full Text] [Related]
4. Use of calcium channel blockers in hypertrophic cardiomyopathy.
Lorell BH
Am J Med; 1985 Feb; 78(2B):43-54. PubMed ID: 4038850
[TBL] [Abstract][Full Text] [Related]
5. 10-year results and survival of patients with hypertrophic cardiomyopathy treated with calcium antagonists.
Hopf R; Kaltenbach M
Z Kardiol; 1987; 76 Suppl 3():137-44. PubMed ID: 3433866
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hypertrophic obstructive cardiomyopathy with verapamil.
Kaltenbach M; Hopf R; Kober G; Bussmann WD; Keller M; Petersen Y
Br Heart J; 1979 Jul; 42(1):35-42. PubMed ID: 573129
[TBL] [Abstract][Full Text] [Related]
7. Persisting effect of Ca(2+)-channel blockers on left ventricular function in hypertrophic cardiomyopathy after 14 years' treatment.
Hartmann A; Schnell J; Hopf R; Kneissl G
Angiology; 1996 Aug; 47(8):765-73. PubMed ID: 8712479
[TBL] [Abstract][Full Text] [Related]
8. Effects of calcium-channel blocking agents on left ventricular diastolic function in hypertrophic cardiomyopathy and in coronary artery disease.
Bonow RO
Am J Cardiol; 1985 Jan; 55(3):172B-178B. PubMed ID: 3881911
[TBL] [Abstract][Full Text] [Related]
9. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe.
Bonow RO; Ostrow HG; Rosing DR; Cannon RO; Lipson LC; Maron BJ; Kent KM; Bacharach SL; Green MV
Circulation; 1983 Nov; 68(5):1062-73. PubMed ID: 6684510
[TBL] [Abstract][Full Text] [Related]
10. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil.
Sherrid MV; Shetty A; Winson G; Kim B; Musat D; Alviar CL; Homel P; Balaram SK; Swistel DG
Circ Heart Fail; 2013 Jul; 6(4):694-702. PubMed ID: 23704138
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)].
Kaltenbach M; Hopf R; Keller M
Dtsch Med Wochenschr; 1976 Aug; 101(35):1284-7. PubMed ID: 8298
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of atrial fibrillation and syncope induced by calcium-channel blockers in hypertrophic cardiomyopathy.
Doiuchi J; Hamada M; Ochi T; Ito T; Kokubu T
Clin Cardiol; 1985 Mar; 8(3):176-9. PubMed ID: 4038927
[TBL] [Abstract][Full Text] [Related]
13. Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function.
Pacileo G; De Cristofaro M; Russo MG; Sarubbi B; Pisacane C; Calabrò R
Can J Cardiol; 2000 Feb; 16(2):146-52. PubMed ID: 10694584
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical effect of calcium inhibitors in hypertrophic cardiomyopathy compared to the effect of beta-blocking agents. A preliminary report with special reference to the beneficial effect of nifedipine on angina pectoris.
Koide T; Kakihana M; Takabatake Y; Iizuka M; Uchida Y; Ozeki K; Morooka S; Kato A; Tanaka S; Oya T; Momomura S; Murao S
Jpn Heart J; 1981 Jan; 22(1):87-102. PubMed ID: 6111617
[TBL] [Abstract][Full Text] [Related]
15. Verapamil normalizes the response of left ventricular early diastolic filling to cold pressor test in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy.
Dimitrow PP; Surdacki A; Dubiel JS
Cardiovasc Drugs Ther; 1997 Dec; 11(6):741-6. PubMed ID: 9512868
[TBL] [Abstract][Full Text] [Related]
16. Verapamil therapy in infants with hypertrophic cardiomyopathy.
Moran AM; Colan SD
Cardiol Young; 1998 Jul; 8(3):310-9. PubMed ID: 9731645
[TBL] [Abstract][Full Text] [Related]
17. Effects of nifedipine and propranolol combined therapy in patients with hypertrophic cardiomyopathy.
Hopf R; Kaltenbach M
Z Kardiol; 1987; 76 Suppl 3():105-12. PubMed ID: 3433863
[TBL] [Abstract][Full Text] [Related]
18. [Beta-adrenergic blockers and calcium antagonists in hypertrophic cardiomyopathy].
Korovina EP
Klin Med (Mosk); 1998; 76(12):30-5. PubMed ID: 10067289
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy.
Gilligan DM; Chan WL; Joshi J; Clarke P; Fletcher A; Krikler S; Oakley CM
J Am Coll Cardiol; 1993 Jun; 21(7):1672-9. PubMed ID: 8496536
[TBL] [Abstract][Full Text] [Related]
20. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.
Bonow RO; Dilsizian V; Rosing DR; Maron BJ; Bacharach SL; Green MV
Circulation; 1985 Oct; 72(4):853-64. PubMed ID: 4040821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
